Three Cases of COVID-19 Variant Delta With and Without Vaccination — Chengdu City, Sichuan Province, April–May, 2021

Chen, Heng; Mao, Yi; Duan, Zhenhua; Wang, Liang; Cheng, Yue; Dai, Yue; Luo, Haiwei; Xie, W M; Fan, Shuangfeng; Zhou, Yuzhen; Xu, J; Lan, Feng; Hu, Liwen; Liu, Zhu; Liang, Xiangdang; Jiang, Liangshuang; Tuo, Xiaoli

doi:10.46234/ccdcw2021.137

Cited by 3 publications

(5 citation statements)

References 2 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent case series from the China Centers for Disease Control and Prevention reported three cases of COVID-19 delta variant infection with and without vaccination in Chengdu City [111]. Two of the cases were vaccinated with two doses, whereas one case was not vaccinated.…”

Section: Vaccinementioning

confidence: 99%

Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality

Zhang

Dong

Liu

et al. 2022

Clinic Rev Allerg Immunol

356

194

View full text Add to dashboard Cite

The outbreak of the coronavirus disease 2019 , caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an evolving global health crisis. Currently, a number of risk factors have been identified to have a potential impact on increasing the morbidity of COVID-19 in adults, including old age, male sex, pre-existing comorbidities, and racial/ethnic disparities. In addition to these factors, changes in laboratory indices and pro-inflammatory cytokines, as well as possible complications, could indicate the progression of COVID-19 into a severe and critical stage. Children predominantly suffer from mild illnesses due to COVID-19. Similar to adults, the main risk factors in pediatric patients include age and pre-existing comorbidities. In contrast, supplementation with a healthy diet and sufficient nutrition, COVID-19 vaccination, and atopic conditions may act as protective factors against the infection of SARS-CoV-2. COVID-19 vaccination not only protects vulnerable individuals from SARS-CoV-2 infection, more importantly, it may also reduce the development of severe disease and death due to COVID-19. Currently used therapies for COVID-19 are off-label and empiric, and their impacts on the severity and mortality of COVID-19 are still unclear. The interaction between asthma and COVID-19 may be bidirectional and needs to be clarified in more studies. In this review, we highlight the clinical evidence supporting the rationale for the risk and protective factors for the morbidity, severity, and mortality of COVID-19.

show abstract

Section: Vaccinementioning

confidence: 99%

Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality

Zhang

Dong

Liu

et al. 2022

Clinic Rev Allerg Immunol

356

194

View full text Add to dashboard Cite

show abstract

“…SARS-CoV-2 VOCs have continuously been imported into China [21–30] . The nucleic acid detection kits recommended for use in China (mainly for dual or triple targets of ORF1ab, N, and E) can detect VOC infections.…”

mentioning

confidence: 99%

“…The B.1.1.7 (20I/501Y.V1) variants were reported in Beijing, Shanghai, Shandong, and other areas, [21,22] while cases of the B.1.351 (20C/501Y.V2) were reported in Guangdong and Shandong [23,24] . Meanwhile, the B.1.617 variant was recently detected in Chongqing, Sichuan, Zhejiang, Shanghai, Beijing, Guangdong, and Yunnan [25–28] . Chinese scientists have isolated and obtained multiple VOCs.…”

mentioning

confidence: 99%

“…SARS-CoV-2 VOCs have continuously been imported into China. [21][22][23][24][25][26][27][28][29][30] The nucleic acid detection kits recommended for use in China (mainly for dual or triple targets of ORF1ab, N, and E) can detect VOC infections. The next-generation sequencing technology can quickly determine the viral lineage and variants.…”

mentioning

confidence: 99%

“…[23,24] Meanwhile, the B.1.617 variant was recently detected in Chongqing, Sichuan, Zhejiang, Shanghai, Beijing, Guangdong, and Yunnan. [25][26][27][28] Chinese scientists have isolated and obtained multiple VOCs. Recently, with the support of the Ministry of Science and Technology of the People's Republic of China, the Institute for Viral Diseases Control and Prevention has begun leading the implementation of the 16-team, joint COVID-19 Emergency Project (2021YFC0863300) (Figure 1), "SARS-CoV-2 variants monitoring and functional impact analysis."…”

mentioning

confidence: 99%

See 2 more Smart Citations

SARS-CoV-2 Variants: Surveillance, Evaluation, and Challenges

Huang

Tan

2021

Infectious Diseases &Amp; Immunity

View full text Add to dashboard Cite

Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial

Pan

Zeng

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Large-scale vaccination is being implemented globally with CoronaVac, an inactivated vaccine against coronavirus disease 2019 (COVID-19). Immunogenicity and safety profiles of homologous two-dose schedules have been published. We report interim results of immune persistence, and the immunogenicity and safety of a third dose of CoronaVac. Methods In this ongoing, placebo-controlled, double-blind phase 2 trial in 18-to-59-year-olds, we randomly assigned subjects, 1:1:1:1, to one of four schedules to receive a third dose, 28 days or 6 months after two two-dose regimens (14-day or 28-day apart): schedule 1: days 0, 14, 42; schedule 2: days 0, 14, 194; schedule 3: days 0, 28, 56; schedule 4: days 0, 28, 208. For each schedule, participants were randomly assigned to either a medium-dose group (3 μg per 0.5 mL of aluminum hydroxide diluent per dose), a high-dose group (6 μg), or a placebo group (2:2:1). The primary outcome was geometric mean titers (GMTs) of neutralizing antibody to live SARS-CoV-2. Results Overall, 540 participants received a third dose. In the 3 μg group, neutralizing antibody titers induced by the first two doses declined after 6-8 months to below the seropositive cutoff (GMT: 4.1 [95%CI 3.3-5.2] for Schedule 2 and 6.7 [95%CI 5.2-8.6] for Schedule 4). When a third dose was given 6-8 months after a second dose, GMTs assessed 14 days later increased to 137.9 [95%CI 99.9-190.4] for Schedule 2, and 143.1 [95%CI 110.8-184.7] for Schedule 4, approximately 3-fold above Schedule 1 and Schedule 3 GMTs after third doses. Similar patterns were observed for the 6 μg group. The severity of solicited local and systemic adverse reactions reported within 28 days after the third dose were grade 1 to grade 2 in all vaccination cohorts. None of the fourteen serious adverse events were considered to be related to vaccination. Conclusions A third dose of CoronaVac administered 6 or more months after a second dose effectively recalled specific immune response to SARS-CoV-2, resulting in a remarkable increase in antibody levels, and indicating that a two-dose schedule generates good immune memory. Optimizing the timing of a booster dose should take into account immunogenicity, vaccine efficacy/effectiveness, local epidemic situation, infection risk, and vaccine supply. (Funded by the National Key Research and Development Program, Beijing Science and Technology Program and National Science Fund for Distinguished Young Scholars; ClinicalTrials.gov number, NCT04352608.)

show abstract

Three Cases of COVID-19 Variant Delta With and Without Vaccination — Chengdu City, Sichuan Province, April–May, 2021

Cited by 3 publications

References 2 publications

Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality

Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality

SARS-CoV-2 Variants: Surveillance, Evaluation, and Challenges

Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial

Contact Info

Product

Resources

About